Perinatal asphyxia partly affects presepsin urine levels in non-infected term infants.

Asphyxia Biomarkers C-Reactive Protein / analysis Case-Control Studies Humans Infant Lipopolysaccharide Receptors Peptide Fragments Procalcitonin Sepsis / diagnosis

kidney newborn perinatal asphyxia (PA) presepsin (P-SEP) sepsis

Journal

Clinical chemistry and laboratory medicine

ISSN: 1437-4331

Titre abrégé: Clin Chem Lab Med

Pays: Germany

ID NLM: 9806306

Informations de publication

Date de publication:
26 04 2022

Historique:

received: 19 08 2021

accepted: 14 01 2022

pubmed: 4 2 2022

medline: 6 4 2022

entrez: 3 2 2022

Statut: epublish

Résumé

Standard of care sepsis biomarkers such as C-reactive protein (CRP) and procalcitonin (PCT) can be affected by several perinatal factors, among which perinatal asphyxia (PA) has a significant role. In this light, new early sepsis biomarkers such as presepsin (P-SEP) are needed to enact therapeutic strategies at a stage when clinical and laboratory patterns are still silent or unavailable. We aimed at investigating the potential effects of PA on longitudinal P-SEP urine levels. We conducted an observational case-control study in 76 term infants, 38 with PA and 38 controls. Standard clinical, laboratory, radiological monitoring procedures and P-SEP urine measurement were performed at four time-points (first void, 24, 48, 96 h) after birth. Higher (p<0.05) CRP and PCT blood levels at T1-T3 were observed in PA than control infants whilst no differences (p>0.05, for all) at T0 were observed between groups. P-SEP urine levels were higher (p<0.05) in PA at first void and at 24 h while no differences (p>0.05) at 48 and 96 h were observed. No significant correlations were found (p>0.05) between P-SEP and urea (R=0.11) and creatinine (R=0.02) blood levels, respectively. The present results, showed that PA effects on P-SEP were limited up to the first 24 h following birth in absence of any kidney function bias. Data open the way to further investigations aimed at validating P-SEP assessment in non-invasive biological fluids as a reliable tool for early EOS and LOS detection in high-risk infants.

Identifiants

DOI: 10.1515/cclm-2022-0027 PMID: 35112525

pubmed: 35112525

pii: cclm-2022-0027

doi: 10.1515/cclm-2022-0027

doi:

Substances chimiques

Biomarkers 0

Lipopolysaccharide Receptors 0

Peptide Fragments 0

Procalcitonin 0

presepsin protein, human 0

C-Reactive Protein 9007-41-4

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

Pagination

793-799

Informations de copyright

Références

Shane, AL, Sánchez, PJ, Stoll, BJ. Neonatal sepsis. Lancet 2017;14:1770–80. https://doi.org/10.1016/s0140-6736(17)31002-4.

Zea-Vera, A, Ochoa, TJ. Challenges in the diagnosis and management of neonatal sepsis. J Trop Pediatr 2015;61:1–13. https://doi.org/10.1093/tropej/fmu079.

Shane, AL, Stoll, BJ. Neonatal sepsis: progress towards improved outcomes. J Infect 2014;68(1 Suppl):S24–32. https://doi.org/10.1016/j.jinf.2013.09.011.

Keij, FM, Kornelisse, RF, Tramper-Stranders, GA, Allegaert, K. Improved pathogen detection in neonatal sepsis to boost antibiotic stewardship. Future Microbiol 2020;15:461–4. https://doi.org/10.2217/fmb-2019-0334.

Morad, EA, Rabie, RA, Almalky, MA, Gebriel, MG. Evaluation of procalcitonin, c-reactive protein, and interleukin-6 as early markers for diagnosis of neonatal sepsis. Int J Microbiol 2020;2020:8889086. https://doi.org/10.1155/2020/8889086.

Sproston, NR, Ashworth, JJ. Role of C-Reactive protein at sites of inflammation and infection. Front Immunol 2018;9:754. https://doi.org/10.3389/fimmu.2018.00754.

Samsudin, I, Vasikaran, SD. Clinical utility and measurement of procalcitonin. Clin Biochem Rev 2017;38:59–68.

Munteanu, AI, Manea, AM, Jinca, CM, Boia, M. Basic biochemical and hematological parameters in perinatal asphyxia and their correlation with hypoxic ischemic encephalopathy. Exp Ther Med 2021;21:259. https://doi.org/10.3892/etm.2021.9690.

Van Maldeghem, I, Nusman, CM, Visser, DH. Soluble CD14 subtype (sCD14-ST) as biomarker in neonatal early-onset sepsis and late-onset sepsis: a systematic review and meta-analysis. BMC Immunol 2019;20:17. https://doi.org/10.1186/s12865-019-0298-8.

Abudeev, SA, Kiselev, KV, Kruglyakov, NM, Belousova, KA, Lobanova, IN, Parinov, OV, et al.. Cerebrospinal fluid presepsin as a marker of nosocomial infections of the central nervous system: a prospective observational study. Front Neurol 2018;9:58. https://doi.org/10.3389/fneur.2018.00058.

Mussap, M, Puxeddu, E, Burrai, P, Noto, A, Cibecchini, F, Testa, M, et al.. Soluble CD14 subtype (sCD14-ST) presepsin in critically ill preterm newborns: preliminary reference ranges. J Matern Neonatal Med 2012;25(5 Suppl):51–3. https://doi.org/10.3109/14767058.2012.717462.

Wu, J, Hu, L, Zhang, G, Wu, F, He, F. Accuracy of presepsin in sepsis diagnosis: a systematic review and meta-analysis. PLoS One 2015;10:e0133057. https://doi.org/10.1371/journal.pone.0133057.

Zhu, Y, Li, X, Guo, P, Chen, Y, Li, J, Tao, T. The accuracy assessment of presepsin (sCD14-ST) for mortality prediction in adult patients with sepsis and a head-to-head comparison to PCT: a meta-analysis. Therapeut Clin Risk Manag 2019;15:741–53. https://doi.org/10.2147/tcrm.s198735.

Kamel, MM, Abd-Ullah, HF, Ahmed, M, Sayed, E, Aziz, RAA. Presepsin as an early predictor of neonatal sepsis. Int J Pediatr 2021;9:13359–69.

Hashem, HE, Abdel Halim, RM, El Masry, SA, Mokhtar, AM, Abdelaal, NM. The utility of neutrophil CD64 and presepsin as diagnostic, prognostic, and monitoring biomarkers in neonatal sepsis. Int J Microbiol 2020;2020:8814892. https://doi.org/10.1155/2020/8814892.

Koh, JH, Lee, S, Kim, HS, Lee, K, Lee, CS, Yoo, SA, et al.. Development of monitoring system for assessing rheumatoid arthritis within 5 minutes using a drop of bio-fluids. J Clin Med 2020;9:3499. https://doi.org/10.3390/jcm9113499.

Horan, TC, Andrus, M, Dudeck, MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 2008;36:309–32. https://doi.org/10.1016/j.ajic.2008.03.002.

Bertino, E, Di Nicola, P, Varalda, AGG, Occhi, L, Giuliani, F, Coscia, A. Neonatal growth charts. J Matern Neonatal Med 2012;25(1 Suppl):67–9. https://doi.org/10.3109/14767058.2012.664889.

D’Alton, ME, Hankins, GDV, Berkowitz, RL, Bienstock, J, Ghidini, A, Goldsmith, J, et al.. Neonatal encephalopathy and neurologic outcome, second edition report of the american college of obstetricians and gynecologists’ task force on neonatal encephalopathy. Pediatrics 2014;133:e1482-8. https://doi.org/10.1542/peds.2014-0724.

Prechtl, HF. The neurological examination of the full-term newborn infant, 2nd ed. Levenham, Suffolk: The Levenham Press Ltd; 1977.

Sarnat, HB, Sarnat, MS. Neonatal encephalopathy following fetal distress. a clinical and electroencephalographic study. Arch Neurol 1976;33:696–705. https://doi.org/10.1001/archneur.1976.00500100030012.

Gazzolo, D, Pluchinotta, F, Bashir, M, Aboulgar, H, Said, HM, Iman, I, et al.. Neurological abnormalities in full-term asphyxiated newborns and salivary S100B testing: the “Cooperative Multitask against Brain Injury of Neonates” (CoMBINe) international study. PLoS One 2015;10:e0115194. https://doi.org/10.1371/journal.pone.0115194.

Chalak, LF. Inflammatory biomarkers of birth asphyxia. Clin Perinatol 2016;43:501. https://doi.org/10.1016/j.clp.2016.04.008.

Xanthou, M, Fotopoulos, S, Mouchtouri, A, Lipsou, N, Zika, I, Sarafidou, J. Inflammatory mediators in neonatal asphyxia and infection. Acta Paediatr 2002;91(1 Suppl):92–7. https://doi.org/10.1111/j.1651-2227.2002.tb02911.x.

Biolo, G, Di Girolamo, FG, McDonnell, A, Fiotti, N, Mearelli, F, Situlin, R, et al.. Effects of hypoxia and bed rest on markers of cardiometabolic risk: compensatory changes in circulating trail and glutathione redox capacity. Front Physiol 2018;30:1000. https://doi.org/10.3389/fphys.2018.01000.

Zhou, M, Wang, CM, Yang, W-L, Wang, P. Microglial CD14 Activated by iNOS contributes to neuroinflammation in cerebral ischemia. Brain Res 2013;1506:105. https://doi.org/10.1016/j.brainres.2013.02.010.

Hasegawa, K, Ichiyama, T, Isumi, H, Nakata, M, Sase, M, Furukawa, S. NF-κB activation in peripheral blood mononuclear cells in neonatal asphyxia. Clin Exp Immunol 2003;132:261–4. https://doi.org/10.1046/j.1365-2249.2003.02127.x.

Frid, MG, Brunetti, JA, Burke, DL, Carpenter, TC, Davie, NJ, Reeves, JT, et al.. Hypoxia-induced pulmonary vascular remodeling requires recruitment of circulating mesenchymal precursors of a monocyte/macrophage lineage. Am J Pathol 2006;168:659–69. https://doi.org/10.2353/ajpath.2006.050599.

Klokker, M, Kharazmi, A, Galbo, H, Bygbjerg, I, Pedersen, BK. Influence of in vivo hypobaric hypoxia on function of lymphocytes, neutrocytes, natural killer cells, and cytokines. J Appl Physiol 1993;74:1100–6. https://doi.org/10.1152/jappl.1993.74.3.1100.

Pugni, L, Pietrasanta, C, Milani, S, Vener, C, Ronchi, A, Falbo, M, et al.. Presepsin (Soluble CD14 Subtype): reference ranges of a new sepsis marker in term and preterm neonates. PLoS One 2015;10:e0146020. https://doi.org/10.1371/journal.pone.0146020.

Ergor, SN, Yalaz, M, Koroglu, OA, Sozmen, E, Akisu, M, Kultursay, N. Reference ranges of presepsin (soluble CD14 subtype) in term and preterm neonates without infection, in relation to gestational and postnatal age, in the first 28 days of life. Clin Biochem 2020;77:7–13. https://doi.org/10.1016/j.clinbiochem.2019.12.007.

Poggi, C, Vasarri, MV, Boni, L, Pugni, L, Mosca, F, Dani, C. Reference ranges of Presepsin in preterm infants in the first 48 h of life: a multicenter observational study. Clin Chim Acta 2020;508:191–6. https://doi.org/10.1016/j.cca.2020.05.040.

Bersani, I, Pluchinotta, F, Dotta, A, Savarese, I, Campi, F, Auriti, C, et al.. Early predictors of perinatal brain damage: the role of neurobiomarkers. Clin Chem Lab Med 2020;58:471–86. https://doi.org/10.1515/cclm-2019-0725.

Risso, FM, Sannia, A, Gavilanes, DAW, Vles, HJ, Colivicchi, M, Ricotti, A, et al.. Biomarkers of brain damage in preterm infants. J Matern Fetal Neonatal Med 2012;4(1 Suppl):101–4. https://doi.org/10.3109/14767058.2012.715024.

Nagata, T, Yasuda, Y, Ando, M, Abe, T, Katsuno, T, Kato, S, et al.. Clinical impact of kidney function on presepsin levels. PLoS One 2015;10:e0129159. https://doi.org/10.1371/journal.pone.0129159.

Risso, FM, Serpero, LD, Zimmermann, LJ, Gavilanes, AW, Frulio, R, Michetti, F, et al.. Perinatal asphyxia: kidney failure does not affect S100B urine concentrations. Clin Chim Acta 2012;413:150–3. https://doi.org/10.1016/j.cca.2011.09.011.

Nakamura, Y, Hoshino, K, Kiyomi, F, Kawano, Y, Mizunuma, M, Tanaka, J, et al.. Comparison of accuracy of presepsin and procalcitonin concentrations in diagnosing sepsis in patients with and without acute kidney injury. Clin Chim Acta 2019;490:200–6. https://doi.org/10.1016/j.cca.2018.09.013.

Kobayashi, S, Amano, H, Terawaki, H, Kawaguchi, Y, Yokoo, T. Prediction of presepsin concentrations through commensurate decline in kidney function in the elderly. Clin Chim Acta 2020;500:1–9. https://doi.org/10.1016/j.cca.2019.09.012.

Strauss, RG. Neonatal anemia: pathophysiology and treatment. Immunol Invest 1995;24:341–51. https://doi.org/10.3109/08820139509062784.